Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.4901
-0.0928 (-15.92%)
At close: Apr 1, 2025, 4:00 PM
0.5153
+0.0252 (5.14%)
After-hours: Apr 1, 2025, 4:47 PM EST
Palatin Technologies Employees
Palatin Technologies had 30 employees as of June 30, 2024. The number of employees decreased by 4 or -11.76% compared to the previous year.
Employees
30
Change (1Y)
-4
Growth (1Y)
-11.76%
Revenue / Employee
$11,667
Profits / Employee
-$898,407
Market Cap
12.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PTN News
- 1 day ago - Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - PRNewsWire
- 4 days ago - Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - PRNewsWire
- 7 days ago - Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency - PRNewsWire
- 6 weeks ago - Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 - PRNewsWire
- 7 weeks ago - Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - PRNewsWire
- 7 weeks ago - Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - PRNewsWire